Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466087 · ClinicalTrials.gov registry record · Phase 2
Role of Magnesium Supplementation in the Treatment of Depression
A Phase 2 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT02466087 is a Phase 2 study that has completed, run by University of Vermont. The registered enrollment target is 126 participants.
The verdict
NCT02466087, a Phase 2 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The objective of this project is to test the hypothesis that magnesium supplementation will decrease depressive symptoms in adults. This study takes place over 12 consecutive weeks. While the investigators will follow the volunteers for the full 12 weeks volunteers will only take magnesium supplements for 6 consecutive weeks. Volunteers will be randomly assigned to start the supplement at week 1 or week 7. Volunteers will take two supplement two times a day for a total of 248 mg elemental magnesium daily in the form of magnesium chloride. This amount of magnesium is less than the tolerable upper limit of 350 mg per day. The supplements will be provided. Volunteers will be asked to maintain their normal diet for the 12 weeks of the study. The primary outcome measure is the PHQ-9 questionnaire, a validated measure of depression. Secondary measures include the GAD-7 for Anxiety and side effects.
Interventions
- DRUG Mg Cl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466087
The ClinicalTrials.gov registry entry for NCT02466087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mg Cl is the first listed.
NCT02466087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02466087 about?
NCT02466087 is a clinical study titled "Role of Magnesium Supplementation in the Treatment of Depression". The objective of this project is to test the hypothesis that magnesium supplementation will decrease depressive symptoms in adults. This study takes place over 12 consecutive weeks. While the investigators will follow the volunteers for the full 12 weeks volunteers will only take magnesium suppleme...
What is the current status of trial NCT02466087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2015-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02466087?
The interventions under investigation include: Mg Cl (DRUG).
Who is sponsoring clinical trial NCT02466087?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.